Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial.
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
17
2
2021
medline:
24
8
2021
entrez:
16
2
2021
Statut:
ppublish
Résumé
Individualizing a target mean arterial pressure is challenging during the initial resuscitation of patients with septic shock. The Sepsis and Mean Arterial Pressure (SEPSISPAM) trial suggested that targeting high mean arterial pressure might reduce the occurrence of acute kidney injury among those included patients with a past history of chronic hypertension. We investigated whether the class of antihypertensive medications used before the ICU stay in chronic hypertensive patients was associated with the severity of acute kidney injury occurring after inclusion, according to mean arterial pressure target. Post hoc analysis of the SEPSISPAM trial. The primary outcome was the occurrence of severe acute kidney injury during the ICU stay defined as kidney disease improving global outcome stage 2 or higher. Secondary outcomes were mortality at day 28 and mortality at day 90. All patients with chronic hypertension included in SEPSISPAM with available antihypertensive medications data in the hospitalization report were included. We analyzed 297 patients. Severe acute kidney injury occurred in 184 patients, without difference according to pre-ICU exposure to antihypertensive medications. Patients with pre-ICU exposure to angiotensin II receptor blockers had significantly less severe acute kidney injury in the high mean arterial pressure target group (adjusted odd ratio 0.24 with 95% CI [0.09-0.66]; p = 0.006). No statistically significant association was found after adjustment for pre-ICU exposure to antihypertensive medications and survival. Our results suggest that patients with septic shock and chronic hypertension treated with angiotensin II receptor blocker may benefit from a high mean arterial pressure target to reduce the risk of acute kidney injury occurrence.
Identifiants
pubmed: 33591012
doi: 10.1097/CCM.0000000000004872
pii: 00003246-202104000-00028
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e412-e422Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Déclaration de conflit d'intérêts
Dr. Dequin’s institution received funding from Angers University Hospital, the French Ministry of Health, Abionic, Atox Bio, Sphingotec GMBH, Adrenomed, Medspace, Aridis, Merck, Combioxin, GSK, Med-Immune, Genentech INH, Rev-Immune, Faron, Kenta, and Tigenix, and he received support for article research from the French Ministry of Health. Dr. Gonzalez disclosed work for hire. Dr. Teboul received funding from Getinge/Pulsion. Dr. Radermacher’s institution received funding from Deutsche Forschungsgemeinschaft and the German Ministry of Defense. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Références
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017; 43:304–377
De Backer D, Cecconi M, Lipman J, et al. Challenges in the management of septic shock: A narrative review. Intensive Care Med. 2019; 45:420–433
Asfar P, Meziani F, Hamel JF, et al. SEPSISPAM InvestigatorsHigh versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014; 370:1583–1593
Macchia A, Romero M, Comignani PD, et al. Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med. 2012; 40:2768–2772
Kim J, Kim YA, Hwangbo B, et al. Effect of antihypertensive medications on sepsis-related outcomes: A population-based cohort study. Crit Care Med. 2019; 47:e386–e393
Hsieh MS, How CK, Hsieh VC, et al. Preadmission antihypertensive drug use and sepsis outcome: Impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Shock. 2020; 53:407–415
Fliser D, Laville M, Covic A. Ad-Hoc Working Group of ERBPA European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: Part 1: Definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012; 27:4263–4272
Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005; 16:3365–3370
Vaara ST, Pettilä V, Kaukonen KM, et al. Finnish Acute Kidney Injury Study GroupThe attributable mortality of acute kidney injury: A sequentially matched analysis*. Crit Care Med. 2014; 42:878–885
Bagshaw SM, George C, Bellomo R. ANZICS Database Management CommitteeEarly acute kidney injury and sepsis: A multicentre evaluation. Crit Care. 2008; 12:R47
Maheshwari K, Nathanson BH, Munson SH, et al. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018; 44:857–867
Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017; 43:816–828
Fani F, Regolisti G, Delsante M, et al. Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury. J Nephrol. 2018; 31:351–359
Demiselle J, Lerolle N. Non-dialytic treatment of acute kidney injury. Néphrol Thér. 2017; 13:S7–S11
Scott J, Jones T, Redaniel MT, et al. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink. BMC Nephrol. 2019; 20:481
Sileanu FE, Murugan R, Lucko N, et al. AKI in low-risk versus high-risk patients in intensive care. Clin J Am Soc Nephrol. 2015; 10:187–196
Lim HJ, Lee HH, Kim AJ, et al. Renin-angiotensin-aldosterone system blockade in critically ill patients is associated with increased risk for acute kidney injury. Tohoku J Exp Med. 2016; 238:17–23
Suberviola B, Rodrigo E, González-Castro A, et al. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury. Med Intensiva. 2017; 41:21–27
Plataki M, Kashani K, Cabello-Garza J, et al. Predictors of acute kidney injury in septic shock patients: An observational cohort study. Clin J Am Soc Nephrol. 2011; 6:1744–1751
Khanna A, English SW, Wang XS, et al. ATHOS-3 InvestigatorsAngiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017; 377:419–430
Tumlin JA, Murugan R, Deane AM, et al. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) InvestigatorsOutcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018; 46:949–957
Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43:970–976
Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111:2605–2610
Bitker L, Burrell LM. Classic and nonclassic renin-angiotensin systems in the critically ill. Crit Care Clin. 2019; 35:213–227
Lee HW, Suh JK, Jang E, et al. Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis. Kor J Intern Med. 2020 Apr 9[online ahead of print]
Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436:112–116
Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice: Discovery of ACE2 and its role in acute lung injury. Exp Physiol. 2008; 93:543–548
Corrêa TD, Jeger V, Pereira AJ, et al. Angiotensin II in septic shock: Effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med. 2014; 42:e550–e559
Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39:3021–3104
Kelly JG, O’Malley K. Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin Pharmacokinet. 1990; 19:177–196